Article Information
History
- July 10, 2022.
Article Versions
- You are currently viewing Version 1 of this article (July 10, 2022 - 20:42).
- Version 2 (July 27, 2022 - 08:07).
- Version 3 (August 31, 2022 - 11:00).
- Version 4 (September 16, 2022 - 11:18).
- View Version 5, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Agnieszka Lemanska1,*,
- Colm Andrews2,
- Louis Fisher2,
- Benjamin Butler-Cole2,
- Amir Mehrkar2,
- Keith J Roberts3,
- Ben Goldacre2,
- Alex J Walker2,
- The OpenSAFELY Collaborative¥ and
- Brian MacKenna2
- 1Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
- 2Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
- 3Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
- ↵* Corresponding author; email: a.lemanska{at}surrey.ac.uk
Posted July 10, 2022.
The impact of COVID-19 on prescribing of pancreatic enzyme replacement therapy for people with unresectable pancreatic cancer in England. A cohort study using OpenSafely-TPP
